BG
CVS icon

Bahl & Gaynor’s CVS Health CVS Stock Holding History

Bahl & Gaynor’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Hold
14,553
– – 0.01% 232
2025
Q4 		$1.15M Hold
14,553
– – 0.01% 231
2025
Q3 		$1.1M Sell
14,553
-398
-3% -$27.3K 0.01% 229
2025
Q2 		$1.03M Sell
14,951
-1,500
-9% -$98.4K 0.01% 234
2025
Q1 		$1.11M Hold
16,451
– – 0.01% 235
2024
Q4 		$738K Sell
16,451
-278
-2% -$15.6K ﹤0.01% 259
2024
Q3 		$1.05M Sell
16,729
-376
-2% -$21.9K 0.01% 245
2024
Q2 		$1.01M Buy
17,105
+1,272
+8% +$79.6K 0.01% 243
2024
Q1 		$1.26M Buy
15,833
+1,680
+12% +$128K 0.01% 236
2023
Q4 		$1.12M Sell
14,153
-320
-2% -$22.8K 0.01% 237
2023
Q3 		$1.01M Sell
14,473
-846
-6% -$59.9K 0.01% 238
2023
Q2 		$1.06M Sell
15,319
-3,302
-18% -$235K 0.01% 241
2023
Q1 		$1.38M Buy
18,621
+9,534
+105% +$799K 0.01% 227
2022
Q4 		$847K Buy
9,087
+3,548
+64% +$342K 0.01% 247
2022
Q3 		$528K Hold
5,539
– – ﹤0.01% 272
2022
Q2 		$513K Buy
5,539
+139
+3% +$13.6K ﹤0.01% 278
2022
Q1 		$547K Sell
5,400
-110
-2% -$11.6K ﹤0.01% 286
2021
Q4 		$568K Sell
5,510
-225
-4% -$20.8K ﹤0.01% 284
2021
Q3 		$487K Hold
5,735
– – ﹤0.01% 290
2021
Q2 		$479K Sell
5,735
-1,135
-17% -$92.9K ﹤0.01% 296
2021
Q1 		$517K Buy
6,870
+435
+7% +$31.7K ﹤0.01% 292
2020
Q4 		$440K Buy
6,435
+1,700
+36% +$111K ﹤0.01% 289
2020
Q3 		$277K Sell
4,735
-326
-6% -$20.3K ﹤0.01% 306
2020
Q2 		$329K Buy
5,061
+366
+8% +$23K ﹤0.01% 301
2020
Q1 		$279K Sell
4,695
-714
-13% -$47.7K ﹤0.01% 305
2019
Q4 		$402K Sell
5,409
-788
-13% -$55.3K ﹤0.01% 314
2019
Q3 		$391K Sell
6,197
-527
-8% -$31.2K ﹤0.01% 316
2019
Q2 		$366K Sell
6,724
-6,398
-49% -$345K ﹤0.01% 321
2019
Q1 		$708K Sell
13,122
-1,721
-12% -$106K 0.01% 283
2018
Q4 		$973K Sell
14,843
-1,215
-8% -$90.7K 0.01% 255
2018
Q3 		$1.26M Sell
16,058
-884
-5% -$63.2K 0.02% 255
2018
Q2 		$1.09M Sell
16,942
-3,671
-18% -$242K 0.01% 264
2018
Q1 		$1.28M Buy
20,613
+1,075
+6% +$77.1K 0.01% 252
2017
Q4 		$1.42M Buy
19,538
+5,346
+38% +$389K 0.01% 246
2017
Q3 		$1.15M Sell
14,192
-250
-2% -$19.8K 0.01% 252
2017
Q2 		$1.16M Sell
14,442
-480
-3% -$37.9K 0.01% 249
2017
Q1 		$1.17M Buy
14,922
+167
+1% +$13.3K 0.01% 235
2016
Q4 		$1.17M Sell
14,755
-136
-0.9% -$11K 0.01% 230
2016
Q3 		$1.32M Buy
14,891
+288
+2% +$27.2K 0.02% 207
2016
Q2 		$1.4M Buy
14,603
+540
+4% +$53.8K 0.02% 196
2016
Q1 		$1.46M Sell
14,063
-225
-2% -$21.9K 0.02% 188
2015
Q4 		$1.4M Buy
14,288
+115
+0.8% +$11.3K 0.02% 192
2015
Q3 		$1.37M Buy
14,173
+239
+2% +$25.1K 0.02% 190
2015
Q2 		$1.46M Buy
13,934
+2,396
+21% +$245K 0.02% 200
2015
Q1 		$1.19M Buy
11,538
+2,008
+21% +$203K 0.02% 207
2014
Q4 		$918K Buy
9,530
+373
+4% +$32.9K 0.01% 224
2014
Q3 		$729K Buy
9,157
+1,736
+23% +$137K 0.01% 244
2014
Q2 		$559K Buy
7,421
+1,598
+27% +$121K 0.01% 266
2014
Q1 		$436K Buy
5,823
+484
+9% +$34.2K 0.01% 289
2013
Q4 		$382K Buy
5,339
+119
+2% +$7.65K 0.01% 306
2013
Q3 		$296K Buy
5,220
+520
+11% +$31K 0.01% 321
2013
Q2 		$269K Buy
+4,700
New +$272K 0.01% 319

Other funds holding CVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bahl & Gaynor's CVS Position: Q1 2026 in Review

Bahl & Gaynor held its CVS Health (CVS) position steady in Q1 2026 at 14,553 shares worth $1.05M. The position accounts for 0.01% of the portfolio, ranked #232.

Bahl & Gaynor first reported a position in CVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.46M in Q2 2015. 1,873 funds tracked by Wall St. Rank hold CVS as of Q1 2026.

  • Bahl & Gaynor held 14,553 shares of CVS Health worth $1.05M as of Q1 2026.
  • Bahl & Gaynor left its CVS Health share count unchanged in Q1 2026.
  • CVS Health made up 0.01% of Bahl & Gaynor's portfolio in Q1 2026, its #232 holding.
  • Bahl & Gaynor first reported a position in CVS Health in Q2 2013 and has held it in 52 quarters since.
  • Bahl & Gaynor's CVS Health position peaked at $1.46M in Q2 2015.
  • 1,873 funds tracked by Wall St. Rank held CVS Health as of Q1 2026.

Based on Bahl & Gaynor's 13F filing for Q1 2026, filed 7 May 2026.